434 related articles for article (PubMed ID: 22200324)
1. Immunotherapy targeting glioma stem cells--insights and perspectives.
Li Z; Lee JW; Mukherjee D; Ji J; Jeswani SP; Black KL; Yu JS
Expert Opin Biol Ther; 2012 Feb; 12(2):165-78. PubMed ID: 22200324
[TBL] [Abstract][Full Text] [Related]
2. Frontiers in targeting glioma stem cells.
Frosina G
Eur J Cancer; 2011 Mar; 47(4):496-507. PubMed ID: 21185169
[TBL] [Abstract][Full Text] [Related]
3. Immunobiology and immunotherapeutic targeting of glioma stem cells.
Madany M; Thomas TM; Edwards L; Yu JS
Adv Exp Med Biol; 2015; 853():139-66. PubMed ID: 25895711
[TBL] [Abstract][Full Text] [Related]
4. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors.
Ahmed N; Salsman VS; Kew Y; Shaffer D; Powell S; Zhang YJ; Grossman RG; Heslop HE; Gottschalk S
Clin Cancer Res; 2010 Jan; 16(2):474-85. PubMed ID: 20068073
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic targeting of malignant glioma.
Alexandru-Abrams D; Jadus MR; Hsu FP; Stathopoulos A; Bota DA
Anticancer Agents Med Chem; 2014; 14(8):1075-84. PubMed ID: 25175690
[TBL] [Abstract][Full Text] [Related]
6. Cell- and peptide-based immunotherapeutic approaches for glioma.
Yamanaka R
Trends Mol Med; 2008 May; 14(5):228-35. PubMed ID: 18403264
[TBL] [Abstract][Full Text] [Related]
7. Stem cell signature in glioblastoma: therapeutic development for a moving target.
Nakano I
J Neurosurg; 2015 Feb; 122(2):324-30. PubMed ID: 25397368
[TBL] [Abstract][Full Text] [Related]
8. Glioblastoma stem cells.
Tabatabai G; Weller M
Cell Tissue Res; 2011 Mar; 343(3):459-65. PubMed ID: 21253762
[TBL] [Abstract][Full Text] [Related]
9. Targeting cancer stem cells for treatment of glioblastoma multiforme.
Cho DY; Lin SZ; Yang WK; Lee HC; Hsu DM; Lin HL; Chen CC; Liu CL; Lee WY; Ho LH
Cell Transplant; 2013; 22(4):731-9. PubMed ID: 23594862
[TBL] [Abstract][Full Text] [Related]
10. Cancer stem cells in glioblastoma.
Lathia JD; Mack SC; Mulkearns-Hubert EE; Valentim CL; Rich JN
Genes Dev; 2015 Jun; 29(12):1203-17. PubMed ID: 26109046
[TBL] [Abstract][Full Text] [Related]
11. [Progress in the study of brain tumor stem cells as treatment targets].
Hide T; Kuratsu J
Brain Nerve; 2009 Jul; 61(7):781-9. PubMed ID: 19618855
[TBL] [Abstract][Full Text] [Related]
12. Stemness Marker Detection in the Periphery of Glioblastoma and Ability of Glioblastoma to Generate Glioma Stem Cells: Clinical Correlations.
Raysi Dehcordi S; Ricci A; Di Vitantonio H; De Paulis D; Luzzi S; Palumbo P; Cinque B; Tempesta D; Coletti G; Cipolloni G; Cifone MG; Galzio R
World Neurosurg; 2017 Sep; 105():895-905. PubMed ID: 28559081
[TBL] [Abstract][Full Text] [Related]
13. Truncated Glioma-Associated Oncogene Homolog 1 (tGLI1) Mediates Mesenchymal Glioblastoma via Transcriptional Activation of CD44.
Rimkus TK; Carpenter RL; Sirkisoon S; Zhu D; Pasche BC; Chan MD; Lesser GJ; Tatter SB; Watabe K; Debinski W; Lo HW
Cancer Res; 2018 May; 78(10):2589-2600. PubMed ID: 29463580
[TBL] [Abstract][Full Text] [Related]
14. Enhanced immunosuppression by therapy-exposed glioblastoma multiforme tumor cells.
Authier A; Farrand KJ; Broadley KW; Ancelet LR; Hunn MK; Stone S; McConnell MJ; Hermans IF
Int J Cancer; 2015 Jun; 136(11):2566-78. PubMed ID: 25363661
[TBL] [Abstract][Full Text] [Related]
15. [Dendritic cell therapy for malignant glioma].
Yamanaka R; Homma J; Yajima N; Tsuchiya N; Tanaka R
No To Shinkei; 2003 Sep; 55(9):771-80. PubMed ID: 14571839
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of immunomodulation in human glioblastoma.
Avril T; Vauleon E; Tanguy-Royer S; Mosser J; Quillien V
Immunotherapy; 2011 Apr; 3(4 Suppl):42-4. PubMed ID: 21524170
[TBL] [Abstract][Full Text] [Related]
17. Armed hunter killers: discerning the role of adoptive T-cell transfer for glioblastoma.
Samaha H; El Naggar S; Ahmed N
Immunotherapy; 2015; 7(5):481-5. PubMed ID: 26065474
[No Abstract] [Full Text] [Related]
18. The status of the art of human malignant glioma management: the promising role of targeting tumor-initiating cells.
Florio T; Barbieri F
Drug Discov Today; 2012 Oct; 17(19-20):1103-10. PubMed ID: 22704957
[TBL] [Abstract][Full Text] [Related]
19. Determinants for Effective ALECSAT Immunotherapy Treatment on Autologous Patient-Derived Glioblastoma Stem Cells.
Wenger A; Werlenius K; Hallner A; Thorén FB; Farahmand D; Tisell M; Smits A; Rydenhag B; Jakola AS; Carén H
Neoplasia; 2018 Jan; 20(1):25-31. PubMed ID: 29190492
[TBL] [Abstract][Full Text] [Related]
20. The Safety of available immunotherapy for the treatment of glioblastoma.
Farber SH; Elsamadicy AA; Atik AF; Suryadevara CM; Chongsathidkiet P; Fecci PE; Sampson JH
Expert Opin Drug Saf; 2017 Mar; 16(3):277-287. PubMed ID: 27989218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
